Nörokütan Hastalıkların Hematolojik-Onkolojik Bulguları ve Yönetimi
Özet
Nörokutanöz genetik bozukluklar; nörofibromatozis tip 1 ve 2, tüberoskleroz, ataksi-telanjiektazi, Von Hippel-Lindau hastalığı ve CMMRD sendromu gibi çeşitli hastalıkları kapsayan, tümör gelişimine yatkınlık oluşturan karmaşık klinik durumlardır. Bu hastalıkların tanı ve yönetimi; spesifik klinik kriterler, genetik testler, radyolojik görüntüleme ve organ sistemlerine özgü düzenli tarama protokollerini gerektirir. Tedavi süreçleri, hastalığın türüne ve tümörlerin karakterine göre cerrahi rezeksiyon, mTOR inhibitörleri gibi medikal yaklaşımlar veya malignite takibini içeren multidispliner bir yaklaşımı zorunlu kılar.
Neurocutaneous genetic disorders encompass complex clinical conditions that predispose individuals to tumor development, including neurofibromatosis types 1 and 2, tuberous sclerosis, ataxia-telangiectasia, Von Hippel-Lindau disease, and CMMRD syndrome. Diagnosis and management of these conditions require specific clinical criteria, genetic testing, radiological imaging, and regular screening protocols tailored to specific organ systems. Treatment strategies necessitate a multidisciplinary approach involving surgical resection, medical interventions such as mTOR inhibitors, or close monitoring for malignancy, depending on the disease type and tumor characteristics.
Referanslar
Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010 Feb;152A(2):327-332.
Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997 Jul 2;278(1):51-7.
Sellmer L, Farschtschi S, Marangoni M, et al. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1. Orphanet J Rare Dis. 2018 Apr 23;13(1):62.
Alhashem F, Yilmaz E, Ozdemir MA, et al. Biliary Rhabdomyosarcoma in an Infant Male With Neurofibromatosis Type 1. J Pediatr Hematol Oncol. 2019 Jan;41(1):e24-e26.
Bachir S, Shah S, Shapiro S, et al. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis. Int J Mol Sci. 2021 Jan 12;22(2):690.
Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009 Jun 19;4:16.
Smith MJ, Bowers NL, Bulman M, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology. 2017 Jan 3;88(1):87-92.
Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008 Aug 23;372(9639):657-668.
Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013 Oct;49(4):255-265.
Canpolat M, Per H, Gumus H, et al. Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86. Childs Nerv Syst. 2014 Feb;30(2):227-240.
Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006 Apr;43(4):289-294.
Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2013 May 16;121(20):4036-4045.
Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003 Jun 14;361(9374):2059-2067.
Jonasch E, McCutcheon IE, Waguespack SG, et al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011 Dec;22(12):2661-2666.
Durno C, Boland CR, Cohen S, et al. Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017 May;152(6):1605-1614.
Wimmer K, Kratz CP, Vasen HF, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). J Med Genet. 2014 Jun;51(6):355-365.
Lavoine N, Colas C, Muleris M, et al. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J Med Genet. 2015 Nov;52(11):770-778.
Aydın F, Altay D, Görükmez O, et al. Glioblastoma and Colorectal Adenocarcinoma in an Adolescent Girl with Constitutional Mismatch Repair Deficiency Syndrome Mimicking Neurofibromatosis Type-I. J Pediatr Acad 2020; 1(1): 34-38.
Tabori U, Hansford JR, Achatz MI, et al. Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood. Clin Cancer Res. 2017 Jun 1;23(11):e32-e37.
Kebudi R, Amayiri N, Abedalthagafi M, et al. Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low-resource settings. Pediatr Blood Cancer. 2020 Aug;67(8):e28309.
